{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:10Z","timestamp":1793885710139,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UDK 106829"],"award-info":[{"award-number":["UDK 106829"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA078902"],"award-info":[{"award-number":["P01-CA078902"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA015704"],"award-info":[{"award-number":["P30-CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA018029"],"award-info":[{"award-number":["P01-CA018029"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.07.023","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:17Z","timestamp":1784678417000},"page":"1459.e1-1459.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-6260","authenticated-orcid":false,"given":"Margery","family":"Gang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0492-7547","authenticated-orcid":false,"given":"Anne-Chloe","family":"Olix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-9911","authenticated-orcid":false,"given":"Gurbani","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazal","family":"Yakub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-1807","authenticated-orcid":false,"given":"Ryan S.","family":"Basom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Markey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Stirewalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9646-6216","authenticated-orcid":false,"given":"Laura S.","family":"Connelly-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2026.07.023_bib0001","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.023_bib0002","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3324\/haematol.2015.132860","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"101","author":"Storb","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.023_bib0003","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \"when and for whom\" in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.023_bib0004","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"24","key":"10.1016\/j.jtct.2026.07.023_bib0005","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood.2024024247","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old","volume":"145","author":"Walter","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.023_bib0006","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/hematology.2025000738","article-title":"New age HCT conditioning regimens: what works and why?","volume":"2025","author":"Ali","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.023_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bmt.1702542","article-title":"A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 106 CD34+ cells\/kg be considered the minimum threshold?","volume":"26","author":"Singhal","year":"2000","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.023_bib0008","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V99.8.2726","article-title":"Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation","volume":"99","author":"Bittencourt","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.023_bib0009","first-page":"88","article-title":"Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies","volume":"28","author":"Gauntner","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.023_bib0010","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2002-11-3503","article-title":"Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation","volume":"102","author":"Perez-Simon","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2026.07.023_bib0011","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2009-03-208355","article-title":"Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose","volume":"114","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.023_bib0012","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.bbmt.2014.05.021","article-title":"Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome","volume":"20","author":"T\u00f6rl\u00e9n","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.023_bib0013","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3324\/haematol.2015.134841","article-title":"Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation","volume":"101","author":"Martin","year":"2016","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.jtct.2026.07.023_bib0014","doi-asserted-by":"crossref","first-page":"27255","DOI":"10.18632\/oncotarget.8463","volume":"7","author":"Czerw","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.023_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells14040290","article-title":"Significance of measurable residual disease in patients undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"14","author":"Gang","year":"2025","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.jtct.2026.07.023_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142323","article-title":"CD34+ cell dose, measurable residual disease, and outcome after myeloablative HLA-matched peripheral blood hematopoietic cell transplantation for adults with acute myeloid leukemia","volume":"17","author":"Gang","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.023_bib0017","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.023_bib0018","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.023_bib0019","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.jtct.2026.07.023_bib0020","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.023_bib0021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41375-022-01574-5","article-title":"Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"36","author":"Zarling","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.023_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70310","article-title":"Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission","volume":"10","author":"Le","year":"2026","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2026.07.023_bib0023","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-62703-357-2_8","article-title":"Flow cytometric monitoring of residual disease in acute leukemia","volume":"999","author":"Wood","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.023_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cyto.b.21239","article-title":"Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry","volume":"90","author":"Wood","year":"2016","journal-title":"Cytom B Clin Cytom"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.023_bib0025","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.023_bib0026","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.023_bib0027","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: is it time to move toward a minimal residual disease-based definition of complete remission","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.023_bib0028","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.023_bib0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.2022.281631","article-title":"Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"108","author":"Rodr\u00edguez-Arbol\u00ed","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.023_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.023_bib0031","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.023_bib0032","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood-2003-07-2534","article-title":"Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation","volume":"103","author":"Chen","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.023_bib0033","first-page":"589.e1","article-title":"Higher dose of CD34+ cells promotes early reconstitution of natural killer cells and is associated with better outcomes after unmanipulated hematopoietic stem cell transplantation for myeloid malignancies","volume":"28","author":"Zhao","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.023_bib0034","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood.V98.12.3221","volume":"98","author":"Zaucha","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.023_bib0035","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.leu.2403718","article-title":"High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation","volume":"19","author":"Baron","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.023_bib0036","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:18:17Z","timestamp":1793884697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726005786"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}